Sanofi delivers positive data on GLP-1 drug for diabetes; Takeda, Lundbeck submit app for FDA approval of antidepressant

Conversations on Twitter :

 @FierceBiotech: J&J, Lilly and Boehringer tout data on SGLT2 drugs for diabetes. More | Follow @FierceBiotech

 @JohnCFierce: BioInvent in Sweden takes out the ax again and chops 20 jobs, the survivors are focusing on cancer drugs. Release | Follow @JohnCFierce

 @RyanMFierce: Sanofi/Genzyme's late-stage Gaucher pill hits goal in late-stage study, next-gen treatment for rare LSD. More | Follow @RyanMFierce

> Sanofi ($SNY) reported upbeat efficacy data on its GLP-1 drug Lyxumia. Article

> Takeda and Danish drugmaker Lundbeck have filed their application for approval of a new antidepressant called vortioxetine with the FDA. Report

> Bristol-Myers Squibb ($BMY) has named Frances Heller as the pharma giant's senior vice president of business development, following the departure of former BMS dealmaker Jeremy Levin, who was named the new CEO of Teva ($TEVA). Release

> Biophytis has found 2 million euros from investors such as the Merck Serono spin-off Metabrain Research to fuel development of products for age-related and metabolic conditions. Item

> The European Commission has approved Novartis' ($NVS) Seebri Breezhaler for patients with COPD. Report

> Novartis faces a moment of truth about its move into the vaccines business with a pending regulatory decision on its meningitis B vaccine. Article

> Third Rock Ventures has named Felix Frueh, an expert in personalized medicine, as an entrepreneur-in-residence. Release

Medical Device News

 @FierceMedDev: Out of the mind of a Ph.D student- a new test for glucose levels using sweat, urine or tears. More | Follow @FierceMedDev

 @MarkHFierce: The FDA wants a judge to dismiss a lawsuit by ex-device center employees accusing the agency of spying on them. Article | Follow @MarkHFierce

 @DamianFierce: Welch Allyn touts its easy-to-use, iPhone-based eye exam device. Story | Follow @DamianFierce

> FDA cites Zimmer for hip replacement manufacturing shortfalls. Article

> AutoGenomics gives IPO another go with $65M offering. Story

Pharma News

@FiercePharma: Kaiser, Washington Post team up for look at co-pay coupons. Upshot: Good for patient, but not for payer. More | Follow @FiercePharma

> More payers than expected cover Vivus' Qsymia. Story

> Merck's Gardasil deemed safe in another large study. Report

Pharma Manufacturing News

> Drugs for illegal Internet pharmacy made in India, Mexico. Report

> China's Tianyin moves ahead with plant as profit plummets. Story

> FDA tries to teach consumers of Internet dangers. Article

Biotech Research News

> Study: Impropriety affects retracted research more than honest mistakes. Article

> New drug target could halt age-related immune system declines. Story

> UC Davis: Induced pluripotent stem cells resemble cancer cells. Report

> Avatar mice up ante for personalized drug treatment research. Item

And Finally… Researchers found that an alarming number of biomedical and life sciences papers had to be retracted after publication because of misconduct or fraud rather than honest mistakes. Article

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.